Alumis
NASDAQ: ALMSSouth San Francisco, US · 8 known investors
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
AI & Machine LearningBiotechDigital HealthHealthtechLongevity
Founders & leadership
MB
Martin BablerPresident, Chief Executive Officer and Chairman of the Board
MB
Mark BradleyChief Development Officer
KB
Kolbot BySVP, Head of Technical Operations
JD
Jack DanilkowiczChief Commercial Officer
JD
Jörn DrappaChief Medical Officer
DM
David M GoldsteinChief Scientific Officer
GH
Grace HaltehSVP, Head of Quality and Regulatory
RH
Roy HardimanChief Business and Strategy Officer
CL
Claire LangrishSVP, Head of Immunology and Translational Science
SP
Sanam PangaliChief Legal Officer and Corporate Secretary
JS
John SchroerChief Financial Officer
Investors · 8
Funding
SEC filings, press & company announcements- Undisclosed amountpublic offeringJan 2026Source ↗
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapExelixis129 shared keywordsExelixis is a biopharmaceutical company developing cancer therapies through biotherapeutics and small molecule programs, including bispecific antibodies and antibody-drug conjugates. It advances anti-cancer treatments internally and via industry collaborations across multiple modalities in biologics and small molecules.
IQVIA110 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Companies competing with Alumis for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Alumis do?
- Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
- Who are Alumis's investors?
- Alumis's investors include Foresite Capital, Nextech Invest, OrbiMed, Samsara BioCapital, SR One Capital Management, venBio Partners, Westlake Village BioPartners, venBio Global Strategic.
- Where is Alumis headquartered?
- Alumis is headquartered in South San Francisco, US.